Bariatric and metabolic surgery, particularly Roux-en-Y gastric bypass, significantly reduced triglyceride, LDL, and non-HDL cholesterol levels over a mean follow-up of 16.9 months.
Observational (n=123)
No
Does bariatric and metabolic surgery improve lipid profiles in patients with severe obesity?
Bariatric and metabolic surgery, particularly Roux-en-Y gastric bypass, significantly improves lipid profiles in patients with severe obesity, contributing to cardiovascular risk reduction.
Aim: Obesity and co-existing metabolic comorbidities are associated with increased cardiovascular (CV) morbidity and mortality risks, generally clustered to risk factors such as dyslipidemia. The aim of this study was to evaluate the lipid profile changes in subjects with severe obesity undergoing different procedures of bariatric and metabolic surgery (BMS), sleeve gastrectomy (SG), and Roux-en-Y gastric bypass (RYGB) in a real-world, clinical setting. Methods: A single-center, retrospective, observational clinical study was performed enrolling patients undergoing BMS. The primary outcome was the change in total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) cholesterol, and triglycerides. Results: In total, 123 patients were enrolled (males 25.2% and females 74.8%) with a mean age of 48.2 ± 7.9 years and a mean BMI of 47.0 ± 9.1 kg/m2. All patients were evaluated until 16.9 ± 8.1 months after surgery. Total and HDL cholesterol did not change after surgery, while a significant reduction in triglyceride levels was recorded. Moreover, a rapid decline of both LDL and non-HDL cholesterol among follow-up visits was observed. In particular, significant inverse correlations were found between total cholesterol, LDL cholesterol, non-HDL cholesterol, and triglycerides and the number of months elapsed after bariatric surgery. Similarly, a direct correlation was found considering HDL cholesterol. Moreover, total cholesterol, LDL cholesterol, non-HDL cholesterol, and triglycerides significantly changed among visits after RYGB, while no changes were observed in the SG group. Finally, considering lipid-lowering therapies, the improvement in lipid asset was detected only in non-treated patients. Conclusion: This study corroborates the knowledge of the improvement in lipid profile with BMS in clinical practice. Together with sustained weight loss, the BMS approach efficiently corrects dyslipidemia, contributing to decreasing the CV risk.
Greco et al. (2022) conducted an observational in Severe obesity (n=123). Bariatric and metabolic surgery (sleeve gastrectomy and Roux-en-Y gastric bypass) was evaluated on Change in total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL) cholesterol, and triglycerides. Bariatric and metabolic surgery, particularly Roux-en-Y gastric bypass, significantly reduced triglyceride, LDL, and non-HDL cholesterol levels over a mean follow-up of 16.9 months.